Registered outcomes12

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

1 to 12 of 12

List	Outcome	Time frame
Primary	SHR-1316 serum trough concentration (Ctrough)	Day1 pre-dose to Day28.
Primary	Area under the concentration curve from time 0 to 21 days for SHR-1316 (sc) (AUC0-21d)	Day1 pre-dose to Day21.
Primary	Area under the concentration curve from time 0 to 28 days for SHR-1316 (sc) (AUC0-28d)	Day1 pre-dose to Day28.
Secondary	Maximum Concentration of SHR-1316 (sc) (Cmax)	Day1 pre-dose to Day28.
Secondary	Time to maximum plasma concentration (Tmax)	Day1 pre-dose to Day28.
Secondary	Terminal half-life (t1/2)	Day1 pre-dose to Day28.
Secondary	Incidence and severity of adverse events (AEs)	About 2 years.
Secondary	Objective Response Rate (ORR)	About 2 years.
Secondary	Duration of Relief (DoR)	About 1.5 years.
Secondary	Disease Control Rate (DCR)	About 2 years.
Secondary	Progression-free Survival (PFS)	About 2 years.
Secondary	Overall Survival (OS)	About 3 years.

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT07009457/registered